The underutilization of cardiacmedications of proven benefit, 1990 to 2002
Randall S. Stafford, MD, PhD*,* and
David C. Radley, BA
* Stanford Center for Research in Disease Prevention, Stanford University, Palo Alto, California, USA
Yale University School of Epidemiology and Public Health, New Haven, Connecticut, USA
View larger version (15K):
[in a new window]
|
Figure 1 Reported warfarin use in patients with atrial fibrillation, 1990 to 2002, National Ambulatory Medical Care Survey (NAMCS) and IMS HEALTH, National Disease and Therapeutic Index (NDTI). Data for 2002 are estimated (E) from data for January 2002 through March 2002.
|
|
View larger version (15K):
[in a new window]
|
Figure 2 Reported angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use in patients with congestive heart failure, 1990 to 2002, National Ambulatory Medical Care Survey (NAMCS) and IMS HEALTH, National Disease and Therapeutic Index (NDTI). Data for 2002 are estimated (E) from data for January 2002 through March 2002.
|
|
View larger version (14K):
[in a new window]
|
Figure 3 Reported beta-blocker use in patients with coronary artery disease, 1990 to 2002, National Ambulatory Medical Care Survey (NAMCS) and IMS HEALTH, National Disease and Therapeutic Index (NDTI). Data for 2002 are estimated (E) from data for January 2002 through March 2002.
|
|
View larger version (14K):
[in a new window]
|
Figure 4 Reported aspirin use in patients with coronary artery disease, 1990 to 2002, National Ambulatory Medical Care Survey (NAMCS) and IMS HEALTH, National Disease and Therapeutic Index (NDTI). Data for 2002 are estimated (E) from data for January 2002 through March 2002.
|
|
|
